[Ivacaftor/tezacaftor/elexacaftor (combination with ivacaftor; cystic fibrosis, ≥ 2 years, at least 1 non-class I mutation, including gating mutation, excluding F508del mutation) – Benefit assessment according to §35a Social Code Book V]

Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen
Record ID 32018014457
German
Original Title: Ivacaftor/Tezacaftor/Elexacaftor (Kombination mit Ivacaftor; zystische Fibrose, ≥ 2 Jahre, mindestens 1 Nicht-KlasseI-Mutation, inklusive Gating-Mutation, exklusive F508del-Mutation)
Details
Project Status: Completed
URL for project: https://www.iqwig.de/projekte/a25-62.html
Year Published: 2025
URL for published report: https://www.iqwig.de/download/a25-62_ivacaftor-tezacaftor-elexacaftor_nutzenbewertung-35a-sgb-v_v1-0.pdf
English language abstract: There is no English language summary available
Publication Type: Full HTA
Country: Germany
DOI: https://doi.org/10.60584/A25-62
MeSH Terms
  • Cystic Fibrosis
  • Drug Therapy, Combination
  • Aminophenols
  • Aminopyridines
  • Benzodioxoles
  • Chloride Channel Agonists
  • Dioxoles
  • Indoles
  • Phenylpropionates
  • Pyrazoles
  • Pyridines
  • Pyrrolidines
  • Quinolones
  • Quinolines
  • Child
  • Child, Preschool
  • Adolescent
  • Adult
Keywords
  • Ivacaftor
  • Tezacaftor
  • Elexacaftor
  • Cystic Fibrosis
  • Child – Preschool
  • Child
  • Adolescent
  • Adult
  • Benefit Assessment
Contact
Organisation Name: Institute for Quality and Efficiency in Health Care (IQWiG)
Contact Address: IQWiG, Siegburger Str. 237, 50679 Cologne, GERMANY, Tel: +49(0)221-35685, Fax: +49(0)221-356851
Contact Email: berichte@iqwig.de
Copyright: Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.